



**Meeting of the Strategic Advisory Group of Experts (SAGE) on Immunization  
4-7 April 2022  
Virtual Meeting  
Final Agenda**

**Day 1: Monday, 4 April 2022**

<b>Time</b>	<b>Session</b>	<b>Purpose of session, target outcomes and questions for SAGE</b>	<b>Duration</b>
<b>10:00</b>	<b>Closed SAGE meeting</b>	Preparation of the sessions of the day.	<b>1h</b>
<b>11:00</b>	<b>Break</b>	<b>Break</b>	<b>15 min.</b>
<b>11:15</b>	<b>Opening and welcome – introduction of participants</b>	<b>Opening of the Plenary Meeting by IVB Director.</b>	<b>15 min.</b>
<b>11:30</b>	<b>Global and Regional Reports – Session 1</b>	<b>FOR INFORMATION</b>	<b>2h 30 min.</b>
	Report from the Director of IVB. K. O'BRIEN, WHO. 20 min.  Update from Gavi. S. Berkley, GAVI. 10 min.  Reports from the Regions – including impact of the COVID-19 pandemic and COVID-19 vaccination on immunization services. WHO. 1h  Discussion. 1h		
<b>14:00</b>	<b>Break</b>	<b>Break</b>	<b>30 min.</b>
<b>14:30</b>	<b>IA2030 deep dive: catch-up vaccination – Session 2</b>	<b>FOR RECOMMENDATION</b>	<b>1h 50 min.</b>
	Impact of COVID-19 pandemic on childhood/adolescent immunization coverage and equity. N. MACDONALD and F. OLAYINKA, SAGE members. 10 min.  Country presentation 1. TBC. 10 min.  Country presentation 2. TBC. 10 min.  Opportunities and strategies for immunization recovery, resiliency building, and strengthening. WHO (tbc). 15 min.  Discussion. 65 min.	This session will discuss will discuss the importance and need to urgently recover immunization programmes, build their resiliency, and strengthen for the long term.  SAGE will be asked to review and consider for endorsement the importance for countries to develop and implement strategies to urgently bridge immunity gaps, recover immunization programmes, and build resiliency against future disruptions and health system strains.  SAGE is also asked to provide input and endorse "Guiding Principles for recovering, building resiliency, and strengthening of immunization in 2022 and beyond".	
<b>16:20</b>	<b>End of the day</b>		

**Day 2: Tuesday 5 April 2022**

<b>Time</b>	<b>Session</b>	<b>Purpose of session, target outcomes and questions for SAGE</b>	<b>Duration</b>
<b>10:00</b>	<b>Closed SAGE meeting</b>	Preparation of the sessions of the day. Recap of day 1. Other important discussion items.	<b>1h</b>
<b>11:00</b>	<b>Break</b>	<b>Break</b>	<b>15 min.</b>
<b>11:15</b>	<b>Hepatitis A – Session 3</b>	<b>FOR RECOMMENDATION</b>	<b>2h</b>
	<p>Introduction of the session, objectives and critical questions R. AGGARWAL, SAGE member and WG chair. 5 min.</p> <p>Overview on disease, global epidemiology and available vaccine products hepatitis A disease. K. MELLOU, SAGE Hepatitis A WG member. 10 min.</p> <p>Main outcomes of the systematic review of evidence. N. WALSH, J. TORRES, WHO secretariat – contractors. 20 min.</p> <p>Presentation of the GRADE/ ETR tables. N. NELSON. SAGE Hepatitis A WG member. 10 min.</p> <p>Question and answers Discussion by SAGE members. 25 min.</p> <p>Draft recommendations. R. AGGARWAL, SAGE member and WG chair. 15 min</p> <p>Discussion by SAGE 30 min.</p> <p>Wrap up. R. AGGARWAL, SAGE member.5 min</p>	<p>The purpose of this session is to update the SAGE recommendations on the use of hepatitis A vaccine (2012 Vaccine position paper). This update will be based on :</p> <ul style="list-style-type: none"> <li>- the accrued data on the global prevalence and burden of disease caused by hepatitis A virus infection, including outbreaks since 2012.</li> <li>- the review of latest available data on efficacy, effectiveness, duration of protection, schedules, safety, and cost-effectiveness of internationally available hepatitis A vaccines, considering all dosing and schedules in particular single dose schedules of inactivated vaccine.</li> </ul> <p>The outcome will be a 2022 update of the Hepatitis A vaccine position paper.</p>	
<b>13:15</b>	<b>Break</b>	<b>Break</b>	<b>30 min.</b>
<b>13:45</b>	<b>COVID-19 vaccines – Session 4</b>	<b>FOR RECOMMENDATION</b>	<b>2h 30 min.</b>
	<p>Introduction. H. NOHYNEK, SAGE member. 5 min.</p> <p><b><i>Vaccine product specific recommendations: Cansino</i></b></p> <p>Company presentation. Cansino. 20 min. Questions and answers. 15 min.</p> <p>Evidence review. 20 min.</p> <p>Presentation of draft recommendations including discussion. 30 min.</p> <p><b><i>Infection and vaccination induced immunity</i></b></p> <p>Immunological findings. (tbc). 15 min.</p> <p>Findings from Mathematical modelling. (tbc). 15 min.</p> <p>Discussion. 30 min.</p>	<b>FOR DISCUSSION</b>	
<b>16:15</b>	<b>End of the day</b>		

**Day 3: Wednesday 6 April 2022**

<b>Time</b>	<b>Session</b>	<b>Purpose of session, target outcomes and questions for SAGE</b>	<b>Duration</b>
<b>10:00</b>	<b>Closed SAGE meeting</b>	Preparation of the sessions of the day. Recap of day 2. Other important discussion items.	<b>1h</b>
<b>11:00</b>	<b>Break</b>	<b>Break</b>	<b>15 min.</b>
<b>11:15</b>	<b>Typhoid update – Session 5</b>	<b>FOR INFORMATION</b>	<b>1h 30 min.</b>
	<p>Introduction and framing. K. MULHOLLAND, SAGE member. 5 min.</p> <p>Updates on global burden and AMR. J. CRUMP, U. of Otago. 10 min.</p> <p>TCV evidence emerging from TyVAC and other studies (incl data on efficacy/effectiveness, immunogenicity, safety, co-admin, use in special populations). K. NEUZIL, SAGE member. 25 min.</p> <p>Discussion. 15 min.</p> <p>Update on TCV pipeline and emerging evidence on single dose vs. primary + booster doses. M. CAREY, U. of Cambridge. 10 min.</p> <p>Overview of country demand and uptake, operational lessons from early TCV introduction. J. WALDORF, WHO. 10 min.</p> <p>Discussion. 15 min.</p>	<p>Update on new evidence from prequalified typhoid conjugate vaccines (TCVs) and late-stage vaccine candidates on vaccine efficacy and effectiveness, immunogenicity and safety; data from special populations; data from older age groups; tolerability and non-interference in immune responses with routine EPI vaccines.</p> <p>The Secretariat does not expect that the data available will support revised TCV policy recommendations at this time. However, SAGE is being requested to make a statement in its report on the new evidence from prequalified TCVs (particularly on vaccine efficacy), to inform country decision making for ongoing TCV introductions.</p>	
<b>12:30</b>	<b>Break</b>	<b>Break</b>	<b>30 min.</b>
<b>13:30</b>	<b>HPV – Session 6</b>	<b>FOR RECOMMENDATION</b>	<b>2h 30 min</b>
	<p>Agenda</p> <p>Session introduction and key questions. R AGGARWAL. SAGE member and WG chair. 5 min.</p> <p>Update on progress of HPV vaccine introduction and reaching the 2030 target of 90% coverage. P. BLOEM, WHO. 10 min.</p> <p>Global market study on HPV vaccines, 2022 Update. T. CERNUSHI. WHO. 10 min.</p> <p>Evidence on single-dose HPV vaccine schedules to inform decision making on reduced schedules. L. MARKOVITZ, SAGE WG member. 10 min</p> <p>Systematic review of evidence on HPV vaccine. N. HENSCHKE, Cochrane Response. 10 min.</p> <p>Modelling evidence on the impact of 1-dose strategies. M. BRISSON, Laval University. 10 min.</p> <p>Discussion on the evidence. 45 min.</p> <p>Conclusions and proposed recommendations by SAGE Working Group. R AGGARWAL, SAGE member and WG chair. 10 min.</p> <p>Discussion on the recommendations. 40 min.</p>	<p>Present SAGE with updated evidence on single dose HPV vaccination schedule, and modelling of impact of HPV immunization schedules and strategies in the context of supply constraint.</p> <p>SAGE is requested to consider the following questions:</p> <ul style="list-style-type: none"> <li>• What is the current HPV vaccine uptake and what are the main barriers for access to HPV vaccines?</li> <li>• What does current evidence show on the immunogenicity and efficacy of a single dose of HPV vaccine and different intervals between the first and second doses of HPV vaccine? And what are the risks of bias of these studies?</li> <li>• What are the potential demand scenarios and the supply of HPV vaccines (short and mid-term outlook) and what could the enhanced HPV vaccine supply allocation be?</li> <li>• In light of the above conclusions and evidence, how should HPV vaccine introduction be prioritized with respect to impact and feasibility?</li> </ul>	
<b>16:00</b>	<b>End of the day</b>		

**Day 4: Thursday 7 April 2022**

<b>Time</b>	<b>Session</b>	<b>Purpose of session, target outcomes and questions for SAGE</b>	<b>Duration</b>
<b>10:00</b>	<b>Closed SAGE meeting</b>	Preparation of the sessions of the day. Recap of day 3. Other important discussion items.	<b>1h</b>
<b>11:00</b>	<b>Break</b>	<b>Break</b>	<b>15 min.</b>
<b>11:15</b>	<b>Polio – Session 7</b>	<b>FOR RECOMMENDATION</b>	<b>1h 45 min.</b>
	<p>Session overview by Ilesh Jani 5 min.</p> <p>Update from the Global Polio Eradication Initiative. A. O'LEARY, WHO. 10 min.</p> <p>Questions: 15 min.</p> <p>OPV Cessation Planning. O. MACH, WHO. 10 min.</p> <p>Questions: 10 min.</p> <p>Update on nOPV2: assessment of safety data and initial field efficacy evaluation. G. MACKLIN, A. BANDYOPADHYAY, WHO/BMGF. 15 min.</p> <p>Questions: 10 min.</p> <p>Report from SAGE Polio Working Group including remarks on OPV2 use in the European Region. I. JANI, SAGE Member. 10 min.</p> <p>Discussion: 20 min.</p>	<p>SAGE will be informed on the current status of the polio eradication program and of the implementation of the new polio eradication strategy. SAGE will be updated on the updated safety data, and initial field efficacy evaluation of nOPV2.</p> <p>SAGE will be asked to review and consider for endorsement:</p> <ul style="list-style-type: none"> <li>• WG's recommendation on initial planning for OPV cessation</li> <li>• WG's recommendation on literature review on use of OPV2 vaccines</li> </ul>	
<b>13:00</b>	<b>End of SAGE Plenary meeting</b>		
<b>13:00</b>	<b>Break</b>	<b>Break</b>	<b>30 min.</b>
<b>13:30</b>	<b>Closed SAGE session</b>	Meeting wrap up.	<b>2h</b>
<b>15:30</b>	<b>End of final closed meeting</b>		